Phase I/IIa Gene Transfer Clinical Trial for Duchenne Muscular Dystrophy Using rAAVrh74.MCK.GALGT2
Status: Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 09 May 2019
Price : $35 *
At a glance
- Drugs RAAVrh74.MCK.GALGT2 (Primary)
- Indications Duchenne muscular dystrophy
- Focus Adverse reactions
- 06 May 2019 Planned End Date changed from 1 Nov 2020 to 1 Nov 2021.
- 06 May 2019 Status changed from recruiting to active, no longer recruiting.
- 31 Aug 2018 Biomarkers information updated